Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Remus Pharmaceuticals Limited (NSE: REMUS), ISIN INE0O5T01011 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
REMUS last traded at ₹815.30 (+1.86%), with a 52-week range of ₹580.00 to ₹1039.00 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 70.95%, FIIs 5.10%, DIIs 0.43%, mutual funds 0.00%.
EquiSense Score (ECS): 67/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.